Oncoceutics: xCures : to Implement an Intermediate Size Expanded Access Protocol for ONC201 in H3 K27M-mutant Gliomas

(marketscreener.com) LOS ALTOS, Calif., March 12, 2019 /PRNewswire/ -- xCures and Cancer Commons are pleased to announce a collaboration with Oncoceutics to implement an Expanded Access program for ONC201. Part of this Expanded Access program is an intermediate size Expanded Access protocol for ONC201 in patients with H3 K27M-mutant glioma entitled "ONC018: Expanded...http://www.marketscreener.com/news/xCures-to-Implement-an-Intermediate-Size-Expanded-Access-Protocol-for-ONC201-in-H3-K27M-mutant-Gli--28152109/?utm_medium=RSS&utm_content=20190312